Key Highlights

  • enGene (NASDAQ:ENGN) said on November 11, 2026 that it will begin a Biologics License Application for detalimogene by year-end, after new data from pivotal Cohort 1 of its LEGEND trial.
  • Among 120 evaluable patients with BCG-unresponsive non-muscle invasive bladder cancer, 56% achieved a complete response at any time, up from 54% at the prior update.
  • The 12-month landmark complete response rate rose to 24% from 13%, and the estimated share of responders still in response at 12 months rose to 43% from 25%.
  • Treatment-related adverse events occurred in 59% of patients, mostly Grade 1 or 2, with no Grade 4 or 5 events.

What the New Data Showed

The LEGEND update from enGene (NASDAQ:ENGN) used an October 29, 2026 data cutoff, with 120 of 125 enrolled patients evaluable for efficacy. Detalimogene is a non-viral gene therapy delivered directly into the bladder, aimed at patients whose cancer has stopped responding to BCG, the standard immunotherapy, and who otherwise often face removal of the bladder. The complete response rate at any time reached 56%. More important for durability, the median duration of response lengthened to 10.1 months from 8.6, with median follow-up among responders now 12.0 months. Some 97% of evaluable patients remained free of progression to muscle-invasive disease, and 86% avoided cystectomy, including 96% of responders. The safety profile was mild: Grade 3 treatment-related events occurred in 4% of patients and serious treatment-related events in 2%. No patient experienced a Grade 4 or 5 treatment-related event, and side effects were generally manageable without stopping therapy.

Why the Filing Plan Matters

The company expects to start its rolling submission by the end of 2026, complete it in the first half of 2027 and potentially win approval in 2027. A non-viral approach is simpler to manufacture than viral gene therapies and can be given in a urology office without special handling, which could help adoption among community urologists who treat most bladder cancer patients. The treatment market for BCG-unresponsive disease has expanded quickly, with several therapies approved or close to approval in recent years, so detalimogene would enter a competitive space. Its pitch will rest on convenience, tolerability and avoiding cystectomy, a major operation that changes quality of life. The company also plans an update in mid-2027 on a cohort using a surfactant bladder rinse designed to improve uptake of the therapy. Results from that cohort could lift response rates further and support future label updates.

Risks to Watch

Durability remains the key question. A 24% complete response rate at 12 months is meaningfully lower than the 56% any-time rate, and regulators and physicians will compare it with rivals that have reported higher sustained responses. The trial is single-arm, which is standard in this setting but leaves cross-trial comparisons open to debate. As a clinical-stage company, enGene (NASDAQ:ENGN) will need funding for a launch, and its spending will rise as it builds a commercial team. Investors should watch the completion of the filing, longer follow-up data and the competitive pricing set by other bladder cancer therapies. Manufacturing scale-up and the ability to Supply community practices quickly after approval will also be tested. Any Partnership with a larger oncology company could ease the funding and commercial burden.

Where Things Stand

enGene reported a 56% complete response rate and improving durability for detalimogene in BCG-unresponsive bladder cancer, with a mild safety profile, and plans to start its BLA by year-end 2026. Approval could come in 2027. The 24% complete response at 12 months will be the main point of comparison with competing therapies, and longer follow-up will decide how the product is positioned. Execution on the rolling submission is the near-term focus.